Bristol Myers announces that KRAZATI in combination with cetuximab demonstrates clinically meaningful activity as a targeted treatment option for patients with previously treated locally advanced or.
Bristol Myers Squibb receives a positive opinion from the CHMP for the CAR T cell therapy Abecma in previous treatment lines for relapsed and refractory triple class multiple myeloma.)This.